Ono Pharmaceutical

Ono Pharmaceutical, a Pharmaceutical Preparation Manufacturing company based in Japan, reported its latest carbon emissions data for 2024. The company's Scope 1 emissions were 7,700,000 kg CO2e, and its Scope 2 emissions (market-based) were 9,800,000 kg CO2e. Key Scope 3 emissions categories included business travel at 4,800,000 kg CO2e, employee commutes at 800,000 kg CO2e, and fuel- and energy-related activities at 3,000,000 kg CO2e.

Looking back, in 2023, Ono Pharmaceutical's Scope 1 emissions were 6,700,000 kg CO2e, and Scope 2 emissions (market-based) were 16,000,000 kg CO2e. Their total Scope 3 emissions for 2023 were 101,900,000 kg CO2e, with purchased goods and services being the largest contributor at 64,000,000 kg CO2e. In 2022, Scope 1 emissions were 8,200,000 kg CO2e, Scope 2 (market-based) were 18,400,000 kg CO2e, and total Scope 3 emissions were 90,800,000 kg CO2e.

Ono Pharmaceutical has set several ambitious climate commitments. The company aims to achieve carbon neutrality for its Scope 1 and 2 emissions by 2025, using carbon offsets. They have also advanced their target for achieving zero greenhouse gas emissions for Scope 1 and 2 to FY2035, from an initial target of FY2050.

Furthermore, Ono Pharmaceutical has Science Based Targets initiative (SBTi) validated commitments. They aim to reduce absolute Scope 1 and 2 GHG emissions by 55% by FY2030 and by 100% by FY2050, from a FY2017 base year. Additionally, they commit to reducing absolute Scope 3 GHG emissions by 30% by FY2030 and by 60% by FY2050, also from a FY2017 base year. These targets are consistent with keeping global warming to 1.5°C.